29 Sep 2026, 08:49 IST
Sun Pharmaceutical Industries Limited
Motilal Oswal Financial Services Ltd. · BUY · target INR 2,310
The report reiterates a Buy rating on Sun Pharma with a target price of INR 2,310 (26% upside), citing tariff exemptions for specialty drugs and European approval of its PCSK9 inhibitor.
From MOStMarketOutlook29092026, written by Motilal Oswal Financial Services Ltd. and hosted by Investment Guru India. Orivam summarised it; the view is Motilal Oswal Financial Services Ltd.'s, not Orivam's.
Open the original PDF on Investment Guru India →Research PDFs are often removed by the firms that publish them. The summary above is kept so this page still means something if that happens.